The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

The main aim of the study is to evaluate how safe and well‑tolerated multiple doses of the medicine are in this patient group. Participants will receive a series of injections over several weeks, with regular clinic visits where vital signs, heart rhythm checks, and blood tests are performed to watch for any unwanted effects. Some participants may receive a harmless inactive substance for comparison, but the study staff will not know which person receives which treatment.

During the study period, blood samples are taken to measure the activity of the clotting protein that is low in this condition, and menstrual blood loss is recorded using a simple diary that helps estimate the amount of blood lost each cycle. After the dosing phase, participants continue to be followed for a short time to ensure any delayed effects are captured. All procedures are designed to be as short and comfortable as possible.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how long patients live without their cancer getting worse, as well as their overall survival. The study will also look at how well the cancer responds to the treatment and how long any positive effects last.

The study aims to provide important information about the effectiveness of these treatment combinations for patients with advanced NSCLC. By comparing these treatments, researchers hope to find the best option for managing this type of lung cancer. The study will continue for several years to gather enough data to make informed conclusions about the treatments’ benefits and safety.

The purpose of the study is to evaluate how the drug affects heart blood flow and tissue characteristics over short and long periods. Participants will receive the medication and undergo a series of heart scans using cardiovascular magnetic resonance (CMR) imaging, a type of MRI that creates detailed pictures of the heart. The scans will measure the myocardial perfusion reserve, which reflects the ability of heart muscle to receive blood, as well as other imaging markers such as tissue signals called T1, T2 and the amount of space outside cells called extracellular volume (ECV) mapping, and a technique called Late Gadolinium Enhancement (LGE) that shows scar tissue. Additional measurements will look at how much work the heart does each beat (stroke work), how efficiently it pumps (ventricular efficiency), its ability to contract (contractility), and the stiffness of the arteries (arterial elastance) using a pressure‑volume analysis (P‑V‑loop‑analysis). Blood flow patterns will also be examined with a technique called 4D flow‑analysis. The size of the heart muscle (myocardial mass) and the volume of the upper left chamber (left atrial volume) will be tracked.

The study will last several years, with participants returning for follow‑up scans at about three months, one year, and two years after starting treatment. Each visit will include the imaging procedures and safety checks, while the medication will be taken daily throughout the study period.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to evaluate how well the VLA15 vaccine works in preventing Lyme disease, as well as to assess its safety and how well it is tolerated by participants. The study will also look at the immune response generated by the vaccine, which is the body’s way of defending itself against infections. Participants in the study will receive a series of injections over a period of time and will be monitored for any reactions or side effects. The study will include people aged 5 years and older who live in areas where Lyme disease is common.

Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects from the vaccine. The study aims to ensure that the vaccine is safe and effective for people of different ages, including children and adults. By participating in this study, researchers hope to gather important information that could lead to a new way to prevent Lyme disease in the future.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The study follows a treatment course made up of several phases. At first, treatment is given to bring the leukemia under control. After that, more treatment is given over time to help keep the disease from returning. Some children may receive only the main drug combination, while others may receive an added medicine based on the type of APL and the level of risk. During the study, doctors watch for side effects and monitor how the disease responds to treatment.

The study is designed for newly diagnosed APL in children and adolescents and compares treatment approaches for different risk groups. The study also examines whether the treatment causes any serious problems and how long children stay in the hospital during therapy.

The purpose of the study is to evaluate how effective and safe litifilimab is in reducing the activity of SLE in adults who are already receiving standard care for lupus that does not involve biologic treatments. Participants in the study will be randomly assigned to receive either litifilimab or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will receive regular injections and attend scheduled visits to monitor their health and the effects of the treatment.

Throughout the study, various aspects of the participants’ health will be assessed, including the activity of their lupus symptoms, any changes in their joint health, and their overall quality of life. The study aims to determine if litifilimab can help reduce the symptoms of SLE and improve the well-being of those affected by this condition. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety during the trial.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

Participants in the study will take the medication NPI-001 orally for a period of up to 12 months. During this time, they will have regular check-ups to monitor their health and any side effects. The study will also look at how often brain bleeding events occur in patients taking the medication. This will help researchers understand if the treatment can reduce these events and improve the condition.

Throughout the study, participants will undergo various assessments, including blood tests, skin biopsies, and MRI scans of the brain. These tests will help track changes in the body and the effects of the treatment. The study aims to provide valuable information on the potential benefits of NPI-001 for people with Hereditary Cystatin C Amyloid Angiopathy.

Participants will be assigned to receive one of the two treatments through the mouth. The study involves monitoring the intensity of mouth pain during and after the use of these medications. This process will take place during radiotherapy, which is a common treatment for cancer that uses radiation to target cells, and for several weeks following the completion of that treatment.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

The purpose of this study is to find out if xaluritamig can help people live longer compared to the other treatment options. Xaluritamig is given as an infusion into a vein, which means it is delivered directly into the bloodstream through a needle. Some people in the study may also receive siltuximab, which is another medicine given through a vein that may help manage certain side effects. The study will also look at whether the cancer stops growing or shrinking, how long any improvements last, whether bone problems are delayed, and how the treatments affect pain and quality of life. Additionally, the study will monitor any unwanted effects or side effects that occur during treatment and will measure how the body processes xaluritamig and whether the body develops any immune response to it.

People joining this study will be randomly assigned to receive either xaluritamig or one of the other treatment options chosen by their doctor. Throughout the study, participants will have regular check-ups that include scans to see how the cancer is responding, blood tests to check overall health and levels of a substance called prostate-specific antigen, and questionnaires to understand how they are feeling and how the treatment is affecting their daily life. The study will continue for several years to gather enough information about how well the treatments work and how safe they are.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of the study is to find out if atorvastatin can prevent the development of active Graves ophthalmopathy in patients who have just been diagnosed with Graves’ disease. Participants will take atorvastatin tablets by mouth for a period of 12 months. The maximum daily dose will be 40 milligrams. During the study, patients will be monitored at several time points over 18 months to check if they develop eye problems and to measure the activity level of any eye inflammation using a scoring system. The study will also look at how the treatment affects quality of life and measure certain antibodies in the blood that are related to the disease.

Throughout the study period, researchers will collect information about whether patients need additional treatments for eye problems, such as corticosteroids or other medications. Blood samples will be analyzed to look for biological markers that might help predict who will respond well to the treatment. The study will also examine genetic differences between people who respond to atorvastatin and those who do not. Patients will complete questionnaires about their quality of life at the beginning of the study, after 12 months, and after 18 months to see how the treatment affects their daily living and well-being.

The purpose of this study is to compare two different lengths of treatment with esomeprazole to see if a shorter treatment period works as well as a longer one in reducing dyspepsia symptoms. Some people in the study will take esomeprazole for seven days, while others will take it for four weeks. The study will measure changes in symptoms using a scoring system called the Glasgow Dyspepsia Severity Score, which tracks how severe the symptoms are over time. The study aims to determine whether the shorter treatment is not worse than the longer treatment, meaning it provides similar relief.

During the study, participants will take esomeprazole by mouth according to their assigned treatment schedule. They will record their symptoms daily so that researchers can track any changes. The maximum daily dose of esomeprazole will be 40 milligrams, and participants may use Rennie as needed for additional symptom relief. The study will last for several weeks, during which time participants will continue to monitor their symptoms. If symptoms do not improve or worsen, participants may be referred for an upper gastrointestinal endoscopy, which is a procedure that allows doctors to look inside the stomach and upper digestive tract using a thin tube with a camera.

The purpose of the study is to compare how well BGB-16673 works against pirtobrutinib in controlling the disease and to evaluate the safety of both treatments. The study will measure how long patients live without their disease getting worse, which is called progression-free survival. This will be assessed by an independent group of medical experts who will review imaging scans and other test results. The study will also look at overall survival, which means how long patients live overall, and will measure how many patients respond to treatment by having their disease shrink or disappear. Additional measurements include how long the treatment response lasts and how long it takes before patients need another treatment for their disease.

During the study, patients will be randomly assigned to receive either BGB-16673 or pirtobrutinib. Both groups will continue taking their assigned medication for up to 42 months unless their disease gets worse or they experience unacceptable side effects. The study will monitor patients for any unwanted effects of the medications and will track how severe these effects are. Patients will also complete questionnaires about their quality of life, including questions about their physical functioning, symptoms, and overall health status. The study will use computed tomography or magnetic resonance imaging scans to measure disease in patients with small lymphocytic lymphoma, looking for lymph nodes that are larger than normal size.

The purpose of this study is to find out if BAY 3713372 is safe, how it affects the body, what side effects it may cause, and whether it can help treat these types of tumors. The study will also determine the right dose of this medicine to use, both when given alone and when combined with other cancer treatments. Additionally, researchers want to understand how the medicine moves through the body and how it may affect tumor growth.

The study will happen in two main parts. In the first part, called dose escalation, different doses of BAY 3713372 will be tested in small groups of people to find a safe and effective dose. Participants will be closely monitored for any side effects, and blood samples will be taken to measure the levels of the medicine in the body. In the second part, called dose expansion, a larger number of people with specific types of MTAP-deleted tumors will receive the selected dose of BAY 3713372, either alone or combined with other cancer treatments. Throughout the study, participants will have regular check-ups, scans to measure their tumors, and blood tests. The treatment is given in cycles, with each cycle lasting 21 days, and participants may continue treatment as long as it is helping them and not causing unacceptable side effects.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

The purpose of the study is to learn how empagliflozin works in the bodies of children and teenagers with chronic kidney disease, to see if it is safe for them, and to find out if it helps their kidney disease. The study will measure how much of the medicine gets into the blood, check for any unwanted effects, and see if the medicine helps improve kidney function. The study will look at changes in protein levels in the urine, which is one way to measure how well the kidneys are working, and changes in how well the kidneys filter waste from the blood.

The study has two parts. In the first part, participants will be randomly assigned to receive either empagliflozin or placebo for 24 weeks, and neither the participants nor the doctors will know which treatment they are receiving. After this period, there will be an open-label extension where all participants will know they are receiving empagliflozin. The total treatment period can last up to 72 weeks. During the study, participants will continue taking their regular medicines for kidney disease, which may include medicines that help protect the kidneys. Regular check-ups will be done to monitor the participants’ health and kidney function throughout the study.

The study will compare the effects of rituximab treatment against placebo to determine if the medication can help with egg retrieval after hormonal stimulation of the ovaries. The treatment involves receiving rituximab through infusion into a vein, with a maximum daily dose of 1 gram and a total dose of up to 4 grams over a 28-day period.

Throughout the study, participants will be monitored for changes in their menstrual cycles, hormone levels, and overall health. The research will track various aspects of ovarian function, including the possibility of natural menstrual periods returning and successful egg retrieval after treatment. The total duration of participation in the study is 19 months, during which various health measurements will be taken to assess the treatment’s effectiveness and safety.

The study involves patients whose lung cancer has already been treated with platinum-based chemotherapy combined with immunotherapy but has since returned. Both medications in this study will be given through intravenous infusion (delivered directly into a vein). GSK5764227 will be given at doses up to 8 milligrams per kilogram of body weight, while topotecan will be given at doses up to 1.5 milligrams per square meter of body surface area.

This is an open-label study, which means both the doctors and patients will know which treatment is being given. The treatment period may last up to 24 months, during which time doctors will monitor how well the cancer responds to the treatment and track the overall survival of patients. Throughout the study, patients will have regular check-ups to monitor their health and assess how well the treatment is working.